In short
This article provides an overview of 2 ongoing clinical trials focused on inflammation. These studies are exploring advanced imaging techniques to visualize inflammatory activity and evaluating safe methods to stop long-term steroid treatment in patients with chronic inflammatory and autoimmune conditions.
Clinical trial locations
- France
- Germany
Study on 68Gallium-FAPI PET/CT Imaging for Patients with Chronic Inflammatory Disorders Using Gallium (68Ga) Chloride and 68-FAPI-46
This clinical trial is testing a special imaging technique to help doctors better see and understand chronic inflammatory conditions in the body. The study uses an advanced scanning method called PET/CT combined with a radioactive tracer known as 68-FAPI-46.
Who can participate: The trial is open to adults aged 18 or over who have been diagnosed with certain chronic inflammatory or fibrotic diseases. These include conditions like rheumatoid arthritis, systemic lupus erythematosus, sarcoidosis, idiopathic pulmonary fibrosis, and scleroderma. Participants must meet the specific classification criteria for their condition and fit the clinical situation being studied.
Who cannot participate: Individuals with certain inflammatory disorders that don't meet the study requirements cannot take part. The trial also excludes people who fall into vulnerable population categories, though specific age ranges beyond the minimum of 18 are not detailed.
What the trial involves: The main focus of this study is to observe how a radioactive tracer called 68Gallium-FAPI behaves in the body when used during a PET/CT scan. The tracer is designed to attach to areas where inflammation and scarring are present in tissues. After a single injection of this tracer, participants undergo a PET/CT scan that captures detailed images of where the tracer accumulates. This helps researchers see the intensity and location of inflammatory activity in different parts of the body. The images are analyzed using a measurement called standardized uptake value, which shows how much of the tracer is present in affected areas.
Investigational drug: The study uses 68Gallium-FAPI, a radiotracer that helps identify and visualize areas of inflammation and fibrosis during imaging. This medication binds to a protein called fibroblast activation protein, which is often found in higher amounts in inflamed or scarred tissues. This binding allows the scanner to create clear pictures of the affected areas.
Study on Stopping Prednisone for Patients with Inflammatory or Autoimmune Disorders
This clinical trial is examining the safest way to stop long-term steroid treatment in patients with inflammatory or autoimmune disorders. The study compares two different approaches: stopping the medication immediately versus gradually reducing the dose over four weeks.
Who can participate: Adults aged 18 or older who have been taking at least 7.5 mg of glucocorticoids daily for at least 28 days can join this study. Participants must have taken a total of at least 420 mg of glucocorticoids before enrolling and must no longer need to gradually reduce their medication to treat their underlying condition. All participants must provide signed informed consent showing they understand the study.
Who cannot participate: The trial excludes patients whose inflammatory or autoimmune disorders still require continued treatment with steroids. Vulnerable populations are also excluded from participation. While the study is open to both male and female patients, those who don't meet the specific gender or age criteria cannot take part.
What the trial involves: The goal of this study is to find out whether stopping steroid medication quickly is as safe and effective as slowly tapering off the dose. Participants are randomly assigned to one of two groups. One group stops their glucocorticoid treatment immediately, while the other group gradually reduces their dose over four weeks. Some participants may receive a placebo, which looks like the medication but doesn't contain the active ingredient. Throughout the 28-day study period, researchers closely monitor participants for any health changes, including signs of adrenal insufficiency. This is a condition where the body doesn't produce enough of certain hormones after stopping steroid treatment. Participants also assess their own general health using a simple scale from 0 to 100.
Investigational drug: The study focuses on glucocorticoids, specifically prednisone, which are medications used to reduce inflammation in the body. These steroids work by binding to specific receptors in cells, which then influences how genes that control inflammation and immune responses are expressed. The trial compares immediate stopping versus gradual reduction of this medication.
Summary
These two clinical trials represent different approaches to managing chronic inflammatory conditions. The French study focuses on improving diagnostic capabilities through advanced imaging with 68Gallium-FAPI PET/CT scanning, offering potential for better visualization of inflammation and fibrosis in various chronic conditions including rheumatoid arthritis, lupus, and sarcoidosis. The German study addresses a practical treatment concern by investigating the safest way to discontinue long-term steroid therapy in patients with inflammatory or autoimmune disorders.
Both trials are currently recruiting participants and aim to provide valuable information that could improve patient care. The imaging study may lead to better monitoring of disease activity, while the steroid withdrawal study could help establish safer protocols for stopping these medications when they are no longer needed. Together, these trials reflect ongoing efforts to both enhance diagnostic tools and optimize treatment strategies for people living with chronic inflammatory conditions.
